Olanzapine-Samidorphan

Indications

• Schizophrenia in adults, delivering olanzapine efficacy with a fixed 10 mg samidorphan component intended to limit weight gain.
• Acute manic or mixed episodes of bipolar I disorder in adults, as monotherapy or as an adjunct to lithium or valproate.
• Maintenance monotherapy treatment of bipolar I disorder in adults after an acute episode has responded.
• Positioned for patients who need olanzapine-level efficacy but for whom weight gain has ended or would end prior olanzapine trials.
• It is not approved and has no established role in opioid use disorder, alcohol use disorder, or any indication of samidorphan alone.

Mechanism of action

• Olanzapine provides the antipsychotic effect through D2 and 5-HT2A antagonism with strong H1 and 5-HT2C blockade.
• Samidorphan is a mu-opioid receptor antagonist with partial agonist activity at kappa and delta receptors.
• Opioid receptor blockade is thought to interrupt the reward and appetite signaling that drives olanzapine-associated weight gain.
• The antipsychotic pharmacology is unchanged, so efficacy, sedation, and anticholinergic effects mirror olanzapine alone.
• Because samidorphan blocks mu receptors, it precipitates withdrawal in opioid-dependent patients and blocks opioid analgesia.

Pharmacokinetics

• Both components are absorbed independently of food, and the fixed-dose tablet must be swallowed whole without splitting or combining strengths.
• Olanzapine is cleared by CYP1A2 and UGT1A4 with a half-life near 35 hours, so smoking status still shifts its levels.
• Samidorphan is metabolized mainly by CYP3A4 with a half-life of roughly 8 hours and no meaningful effect on olanzapine exposure.
• Mu-opioid receptor blockade persists across the dosing interval, which is why opioid analgesia is unreliable during treatment.
• No dose adjustment is needed for mild to moderate renal or hepatic impairment, but severe impairment warrants caution.

Dosing

• Schizophrenia: start 5/10 mg or 10/10 mg once daily, then adjust in 5 mg olanzapine increments weekly to a maximum of 20/10 mg/day.
• Bipolar I mania as monotherapy: start 10/10 mg or 15/10 mg once daily, adjusting no more often than every 24 hours in 5 mg steps.
• As adjunct to lithium or valproate, start at 10/10 mg once daily, with a recommended range of 10/10 to 20/10 mg once daily.
• The samidorphan component is fixed at 10 mg in every strength, so only the olanzapine dose is actually being titrated.
• Patients using opioids must be opioid free for at least 7 days after short-acting and 14 days after long-acting opioids before starting.
• Start at 5/10 mg in those predisposed to hypotension, slower olanzapine metabolism, or heightened pharmacodynamic sensitivity.

Adverse effects

• Weight gain still occurs and averages roughly 4 percent of body weight over 6 months, less than olanzapine alone but far from neutral.
• Sedation, dry mouth, increased appetite, constipation, and dizziness are common and reflect the olanzapine component.
• Hyperglycemia, dyslipidemia, and new-onset diabetes remain real risks and are not eliminated by the opioid antagonist.
• Precipitated opioid withdrawal can be abrupt and severe in a dependent patient and may require emergency management.
• After stopping, reduced opioid tolerance raises the risk of fatal overdose if a patient resumes their previous opioid dose.
• Neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension, and seizures carry the usual antipsychotic-class risk.

Monitoring

• Take a careful opioid history before starting, including buprenorphine, methadone, and as-needed analgesics, and document the opioid-free interval.
• Weight and BMI at baseline and every visit for the first 3 months, then quarterly, with fasting glucose or A1c and lipids at 12 weeks and annually.
• Counsel and document that opioid analgesia will be blocked, and plan non-opioid strategies for any anticipated surgery or injury.
• Blood pressure and orthostatic vitals during titration, particularly in older adults and patients on antihypertensives.
• AIMS examination at baseline and every 6-12 months, plus attention to smoking changes that alter olanzapine levels.

Interactions

• Contraindicated in patients using opioids and in those undergoing acute opioid withdrawal, without exception for analgesic intent.
• Fluvoxamine and other CYP1A2 inhibitors raise the olanzapine component, while carbamazepine and cigarette smoke lower it.
• Strong CYP3A4 inducers reduce samidorphan exposure, which could weaken the weight-mitigating effect but not the antipsychotic action.
• Additive sedation and hypotension with benzodiazepines, alcohol, and antihypertensives, as with olanzapine alone.
• Emergency opioid analgesia requires higher doses under continuous monitoring in a setting equipped for respiratory support.

Special populations

• In pregnancy the opioid antagonist adds risk for any patient on opioid agonist therapy, and third-trimester exposure carries neonatal withdrawal risk.
• Lactation data for samidorphan are absent, and olanzapine passes into milk, so monitor breastfed infants for sedation.
• Safety and effectiveness have not been established in pediatric patients, so use is confined to adults.
• In older adults the olanzapine anticholinergic and orthostatic burden applies, along with the boxed dementia mortality warning.
• Use caution in severe hepatic or renal impairment, and avoid entirely in patients who may need opioid analgesia soon.

Clinical pearls

• Contraindicated with any opioid use; it will precipitate withdrawal and block analgesia.
• Weight mitigation is partial, not protective; metabolic monitoring is unchanged from olanzapine.
• After stopping, lost opioid tolerance makes a previously usual dose potentially fatal.